ISitagliptin phosphate yidipeptidyl peptidase Ⅳ(DDP-4) inhibitor class yamachiza ephuhliswe yinkampani yaseJamani iMerck kwaye yaqala yafumana imvume yoLawulo lokuTya kunye neDrug e-US kunyango lwesifo seswekile se-2, lichiza elitsha le-antidiabetic, linokuphucula umzimba ngokwawo. ukukwazi ukunciphisa amanqanaba aphezulu eswekile yegazi, kunye nokonyuka ngokwendalo kwe-incretin ngokwendalo ngokuthintela umsebenzi wale enzyme, kubandakanywa amanqanaba e-glucagon-like peptide 1 kunye ne-glucose exhomekeke kwi-insulinotropic peptide, ngaloo ndlela ibangela ukuba i-pancreas iphucule imveliso ye-insulin kunye nokuyeka iswekile. ukuveliswa kwesibindi, kwaye ekugqibeleni kuncitshiswe umphumo wekliniki woxinaniso lweglucose yegazi.